Skip to main content

Licensing agreement between Bosch i Gimpera Foundation and Euroimmun

By 3 de September de 2014November 18th, 2020No Comments
< Back to news
Dr. Francesc Graus and Dr. Josep Dalmau.

Licensing agreement between Bosch i Gimpera Foundation and Euroimmun

The German company Euroimmun AG and the Bosch i Gimpera Foundation (FBG) –based in the PCB– have signed an agreement in which the company acquired the rights to the patent for a technology that allows the diagnosis and treat patients suffering from an autoimmune disease and associated neurodegenerative processes disruption of sleep. The German company Euroimmun AG has acquired the rights of a patent for a technology developed by the Hospital Clínic de Barcelona, University of Barcelona (UB), the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Catalan Institute for Research and Advanced Studies (ICREA).

Dr. Francesc Graus, head of Neurology at the Clinic and leader of the IDIBAPS team Clinical and Experimental Neuroimmunology, is the principal inventor of the patent, and Dr. Josep Dalmau, ICREA researcher leading the IDIBAPS group Autoimmunity Against Synaptic Antigens, has also collaborated. Dr. Dalmau is an international reference in the study of neurology and psychiatry and in the past 7 years has identified 8 autoimmune diseases affecting the brain.

Dr. Graus and Dr. Dalmau have developed a technology for the diagnosis, prognosis and treatment of patients with an autoimmune disease associated to sleep disorders. It is based on detecting the presence of antibodies against the neuronal protein IGLON5 by immunocytochemistry of transfected cells.

Lancet Neurology published last April the results now protected by the patent just licensed. Researchers identified the presence of an antibody against a neuronal protein, IgLON5, responsible for a neurodegenerative process linked to the autoimmune process that causes sleep disorders. The development of this technology will diagnose neurodegenerative disease-related sleep disturbances unknown until know, and suggests the possibility of controlling, in the future, inflammatory processes responsible for neurodegeneration in these patients.

For further information [+]